Roche executive says COVID-hit health systems at 'more or less' normal capacity
By Editor - Tue Sep 15, 5:35 am
Many patients have overcome initial fears of COVID-19 infections and resumed doctor visits, Roche’s drug unit chief said, helping health systems even in hard-hit regions like Texas, Florida and California return to “more or less” normal capacity. Swiss-based Roche’s results this year have been dented as patients around the world shied away from hospitals and clinics during lockdowns, lowering demand for drugs including eye medicine Lucentis, multiple sclerosis drug Ocrevus and hemophilia medicine Hemlibra and leading to a 10% second-quarter sales decline. Bill Anderson, CEO of Roche’s main pharmaceuticals unit with about $50 billion in annual sales, said in an interview on Tuesday that most of the world’s health care systems have re-stabilized, “even in places that had reasonably high levels of COVID”.
Go here to read the rest: